What is happening with Crinetics Pharmaceuticals Inc (CRNX) Stock?
Citigroup raised the price target for the Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock to “a Buy”. The rating was released on March 06, 2024, according to finviz. The research report from Jefferies has initiated the stock to Hold, with a price target set at $35. The stock was resumed by JP Morgan, who disclosed in a […]
Crinetics Pharmaceuticals Inc (CRNX) Stock is looking to regain its victory
Citigroup raised the price target for the Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock to “a Buy”. The rating was released on March 06, 2024, according to finviz. The research report from Jefferies has initiated the stock to Hold, with a price target set at $35. The stock was resumed by JP Morgan, who disclosed in a […]
In the long run, Crinetics Pharmaceuticals Inc (CRNX) Stock makes the most sense financially and strategically
Citigroup raised the price target for the Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock to “a Buy”. The rating was released on March 06, 2024, according to finviz. The research report from Jefferies has initiated the stock to Hold, with a price target set at $35. The stock was resumed by JP Morgan, who disclosed in a […]
The future of Crinetics Pharmaceuticals Inc (CRNX) Stock is still in tatters?
Citigroup raised the price target for the Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock to “a Buy”. The rating was released on March 06, 2024, according to finviz. The research report from Jefferies has initiated the stock to Hold, with a price target set at $35. The stock was resumed by JP Morgan, who disclosed in a […]
Why Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) Stock up 4.69% in Last Week?
Citigroup raised the price target for the Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock to “a Buy”. The rating was released on March 06, 2024, according to finviz. The research report from Jefferies has initiated the stock to Hold, with a price target set at $35. The stock was resumed by JP Morgan, who disclosed in a […]
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) Stock is trading Higher 21.15% From 200-Day SMA
Citigroup raised the price target for the Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock to “a Buy”. The rating was released on March 06, 2024, according to finviz. The research report from Jefferies has initiated the stock to Hold, with a price target set at $35. The stock was resumed by JP Morgan, who disclosed in a […]
Why Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) Stock up 0.73% in Last Week?
Citigroup raised the price target for the Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock to “a Buy”. The rating was released on March 06, 2024, according to finviz. The research report from Jefferies has initiated the stock to Hold, with a price target set at $35. The stock was resumed by JP Morgan, who disclosed in a […]
Crinetics Pharmaceuticals Inc (CRNX) Stock: Values And Value Intersection
Citigroup raised the price target for the Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock to “a Buy”. The rating was released on March 06, 2024, according to finviz. The research report from Jefferies has initiated the stock to Hold, with a price target set at $35. The stock was resumed by JP Morgan, who disclosed in a […]
Does A Technical Metric Suggest That Crinetics Pharmaceuticals Inc (CRNX) Stock Is Ready To Rise?
Citigroup raised the price target for the Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock to “a Buy”. The rating was released on March 06, 2024, according to finviz. The research report from Jefferies has initiated the stock to Hold, with a price target set at $35. The stock was resumed by JP Morgan, who disclosed in a […]
Why Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) Stock rose 38.65% in Last Six Months?
Citigroup raised the price target for the Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock to “a Buy”. The rating was released on March 06, 2024, according to finviz. The research report from Jefferies has initiated the stock to Hold, with a price target set at $35. The stock was resumed by JP Morgan, who disclosed in a […]
